Manufacturers report positive date for aflibercept for diabetic retinopathy after 2 years treatment

Data from the Protocol W study found that patients were 68% less likely to develop center-involved diabetic macular oedema (p<0.001) if continued on aflibercept after the initial 4 doses vs switching to sham procedure.

Source:

Biospace Inc.